Barron Signs Off With Notes On GSK Culture Change, Tease On RSV Vaccine Results
Transformation Not Yet Complete, Says Departing R&D Chief
Hal Barron is leaving just as GSK’s M&A firepower grows following the Haleon spin-out, but sounded a confident note about its potential blockbuster RSV vaccine candidate.
You may also be interested in...
GSK’s new chief scientific officer Tony Wood is building on the precision medicine approach by partnering with Tempus to accelerate cancer drug trials and improve the firm’s R&D productivity.
GSK is entering a new era, and CEO Emma Walmsley looks likely to use new finances for more targeted M&A.
GSK has declared success for its RSV vaccine and will begin regulatory talks immediately – but the final efficacy level, as yet unrevealed, could be decisive in a competitive market.